The U.S. Food and Drug Administration issued a Complete Response Letter to Merck & Co. for the company’s New Drug Application for gefapixant for refractory chronic cough or unexplained chronic cough.
The U.S. Food and Drug Administration issued a Complete Response Letter to Merck & Co. for the company’s New Drug Application for gefapixant for refractory chronic cough or unexplained chronic cough.
